OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral
fluid diagnostics, today announced revenues of $17.6 million for
the quarter ended September 30, 2006, compared to $18.1 million in
revenues recorded for the comparable period in 2005. The Company�s
net income was $2.1 million, or $0.05 per share on a basic and
fully-diluted basis, for the third quarter of 2006, which includes
charges for stock option expense and a provision for income taxes,
neither of which were included in the Company�s 2005 results.
Excluding these two charges, net income for the third quarter of
2006 would have been $4.3 million, or $0.09 per share on a
fully-diluted basis. These results compare to net income of $3.8
million, or $0.08 per share on a basic and fully-diluted basis,
during the third quarter of 2005. For the nine months ended
September 30, 2006, the Company had revenues of $50.4 million
compared to revenues of $51.3 million for the nine months ended
September 30, 2005. The Company recorded net income of $4.2
million, or $0.09 per share on a basic and fully-diluted basis, for
the nine months ended September 30, 2006, which includes charges
for stock option expense and a provision for income taxes.
Excluding these two charges, net income for the nine months ended
September 30, 2006 would have been $10.0 million, or $0.21 per
share on a fully-diluted basis. These results compare to net income
of $6.8 million, or $0.15 per share on a basic and fully-diluted
basis, during the nine months ended September 30, 2005, which
excluded costs related to stock options and a provision for income
taxes. �We are pleased with the Company�s financial performance for
the third quarter,� said Douglas A. Michels, President and Chief
Executive Officer of OraSure Technologies. �Our financial results
exceeded our expectations and were driven primarily by continued
strong performance of our infectious disease testing business along
with the increased sales of our substance abuse testing and
insurance risk assessment products. Offsetting these increases was
a reduction in our cryosurgical systems sales.� Gross margin in
both the third quarters of 2006 and 2005 was 64%. Operating
expenses for the third quarter of 2006 increased to $8.8 million
from $8.4 million in the comparable period in 2005. This increase
was primarily attributable to stock option expense, increased
research and development expenses and costs related to the
implementation of a new enterprise resource planning system, offset
by lower legal and advertising costs. Operating expenses for the
nine months ended September 30, 2006 were $27.3 million, compared
to $25.2 million for the comparable period in 2005. Cash, cash
equivalents and short-term investments totaled $89.5 million and
working capital was $98.1 million at September 30, 2006, compared
to $77.6 million and $90.7 million, respectively, at December 31,
2005. Cash flow from operations was $5.9 million for the third
quarter of 2006, up from the $3.6 million reported for the third
quarter of 2005. Cash flow from operations for the nine months
ended September 30, 2006 was $14.1 million, compared to $8.5
million for the comparable period in 2005. Due to the better than
expected financial performance in the third quarter of 2006, the
Company is raising its 2006 full year, fully-diluted earnings per
share guidance to between $0.10 - $0.11 per share as a result of an
additional expected $0.01 - $0.02 per share of earnings in the
fourth quarter of 2006. The fourth quarter earnings projection is
based on attainment of projected revenues of between $17.0 million
and $17.5 million for the quarter, resulting in 2006 full-year
projected revenues of between approximately $67.5 million and $68.0
million. Condensed Financial Data (In thousands, except per-share
data and percentages) Unaudited � Three months endedSeptember 30,
Nine months endedSeptember 30, 2006� 2005� 2006� 2005� Results of
Operations Revenues $ 17,639� $ 18,077� $ 50,421� $ 51,335� Cost of
products sold � 6,365� � 6,432� � 18,516� � 20,773� Gross profit
11,274� 11,645� 31,905� 30,562� Operating expenses: Research and
development 1,753� 1,298� 5,150� 3,750� Acquired in-process
technology �� �� 600� �� Sales and marketing 3,632� 3,965� 11,977�
12,289� General and administrative � 3,445� � 3,168� � 9,545� �
9,132� Total operating expenses � 8,830� � 8,431� � 27,272� �
25,171� Operating income 2,444� 3,214� 4,633� 5,391� Other income,
net 955� 594� 2,642� 1,421� Income tax provision � 1,264� � �� �
3,033� � �� Net income $ 2,135� $ 3,808� $ 4,242� $ 6,812� Earnings
per share Basic $ 0.05� $ 0.08� $ 0.09� $ 0.15� Diluted $ 0.05� $
0.08� $ 0.09� $ 0.15� Shares used in computing earnings per share:
Basic � 45,922� � 45,372� � 45,888� � 44,936� Diluted � 47,247� �
46,676� � 47,712� � 45,850� Reconciliation of Non-GAAP Financial
Measures Three months endedSeptember 30, Nine months endedSeptember
30, 2006� 2005� 2006� 2005� Net income � before charges $ 4,344� $
3,808� $ 9,992� $ 6,812� Stock option expense 945� �� 2,717� ��
Income tax provision � 1,264� � �� � 3,033� � �� Net income � GAAP
basis $ 2,135� $ 3,808� $ 4,242� $ 6,812� � Diluted earnings per
share � before charges $ 0.09� $ 0.08� $ 0.21� $ 0.15� Stock option
expense 0.02� �� 0.06� �� Income tax provision � 0.02� � �� � 0.06�
� �� Diluted earnings per share � GAAP basis $ 0.05� $ 0.08� $
0.09� $ 0.15� Three months ended September 30, Dollars Percentage
ofTotal Revenues Market Revenues 2006� 2005� %Change� 2006� 2005� �
Infectious disease testing $ 7,536� $ 7,037� 7% 42% 39% Substance
abuse testing 4,213� 3,595� 17� 24� 20� Cryosurgical systems 4,025�
6,143� (34) 23� 34� Insurance risk assessment � 1,734� � 1,275� 36�
10� 7� Product revenues 17,508� 18,050� (3) 99� 100� Licensing and
product development � 131� � 27� 385� 1� �� Total revenues $
17,639� $ 18,077� (2)% 100% 100% � Nine months ended September 30,
Dollars Percentage ofTotal Revenues Market Revenues 2006� 2005�
%Change� 2006� 2005� � Infectious disease testing $ 21,239� $
19,672� 8% 42% 38% Substance abuse testing 11,694� 10,060� 16� 23�
20� Cryosurgical systems 13,063� 16,002� (18) 26� 31� Insurance
risk assessment � 4,128� � 5,364� (23) 8� 11� Product revenues
50,124� 51,098� (2) 99� 100� Licensing and product development �
297� � 237� 25� 1� �� Total revenues $ 50,421� $ 51,335� (2)% 100%
100% Balance Sheets September 30,2006 December 31,2005 Assets Cash,
cash equivalents and short-term investments $ 89,534� $ 77,620�
Accounts receivable, net 10,236� 11,602� Inventories 4,812� 4,128�
Current portion of deferred income taxes 3,511� 6,504� Other
current assets 1,646� 1,553� Property and equipment, net 16,478�
5,815� Deferred income taxes 20,580� 20,205� Other non-current
assets � 2,938� � 3,320� Total assets $ 149,735� $ 130,747� �
Liabilities and Stockholders� Equity Current portion of long-term
debt $ 636� $ 456� Accounts payable 2,519� 2,547� Accrued expenses
8,526� 7,734� Long-term debt, less current portion 10,303� 884�
Other liabilities 375� 207� Stockholders� equity � 127,376� �
118,919� Total liabilities and stockholders� equity $ 149,735� $
130,747� Non-GAAP Financial Measures Net income - before charges
and diluted earnings per share - before charges, each exclude the
impact of stock option expensing and income tax provisions. These
financial measures should not be considered an alternative to net
income or diluted earnings per share, respectively, which are
indicators of operating performance determined in accordance with
GAAP. OraSure Technologies believes that net income - before
charges and diluted earnings per share - before charges, although
non-GAAP financial measures, are also useful and meaningful to
investors because they provide investors with the Company�s
underlying earnings performance as another criterion in making
their investment decisions. OraSure�s management also uses these
calculations in measuring certain corporate performance goals.
Other companies may use different measures to present financial
information. Conference Call The Company will host a conference
call and audio webcast today to discuss the Company�s third quarter
2006 financial results and to provide an update on major business
objectives, beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific
Time). On the call will be Douglas A. Michels, President and Chief
Executive Officer, and Ronald H. Spair, Chief Financial Officer and
Chief Operating Officer. The call will include remarks by
management and a question and answer session. In order to listen to
the conference call, please either dial 888-742-2024 (Domestic) or
706-643-0033 (International), or go to OraSure Technologies' Web
site, www.orasure.com, and click on the Investor Info link. A
replay of the call will be archived on OraSure Technologies' web
site shortly after the call has ended and will be available for
seven days. A replay of the call can also be accessed until
November 08, 2006, by dialing 800-642-1687 (Domestic) or
706-645-9291 (International) and entering the Conference ID
#8995949. About OraSure Technologies OraSure Technologies develops,
manufactures and markets oral fluid specimen collection devices and
tests and other diagnostic products using its proprietary
technologies, including immunoassays and other in vitro diagnostic
tests and other medical devices. These products are sold in the
United States and certain foreign countries to clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, distributors, government
agencies, physicians� offices, and commercial and industrial
entities. For more information on the Company, please visit
www.orasure.com. Important Information This press release contains
certain forward-looking statements, including with respect to
revenues and earnings per share. Actual results could be
significantly different. Factors that could affect results include
the ability to market and sell products; changes in relationships
with strategic partners and reliance on strategic partners for the
performance of critical activities under collaborative
arrangements; failure of distributors or other customers to meet
purchase forecasts or minimum purchase requirements for our
products; impact of competitors, competing products and technology
changes; ability to develop, commercialize and market new products;
market acceptance of oral fluid testing or other new products or
technology; changes in market acceptance based on product
performance; continued bulk purchases by customers, including
governmental agencies, and the ability to fully deploy those
purchases in a timely manner; ability to fund research and
development and other products and operations; ability to obtain
and maintain new or existing product distribution channels;
reliance on sole supply sources for critical product components;
availability of related products produced by third parties; ability
to obtain, and timing and cost of obtaining, necessary regulatory
approval for new products or new indications or applications for
existing products; ability to comply with applicable regulatory
requirements; history of losses and ability to achieve sustained
profitability; volatility of our stock price; uncertainty relating
to patent protection and potential patent infringement claims;
uncertainty and costs of litigation relating to patents and other
intellectual property; availability of licenses to patents or other
technology; ability to enter into international manufacturing
agreements; obstacles to international marketing and manufacturing
of products; ability to sell products internationally; loss or
impairment of sources of capital; ability to meet financial
covenants in agreements with financial institutions; ability to
retain qualified personnel; exposure to product liability, patent
infringement, and other types of litigation; changes in
international, federal or state laws and regulations; customer
consolidations and inventory practices; equipment failures and
ability to obtain needed raw materials and components; the impact
of terrorist attacks and civil unrest; ability to complete
consolidation or restructuring activities; ability to identify,
complete and realize the full benefits of potential acquisitions;
and general political, business and economic conditions. These and
other factors are discussed more fully in the Securities and
Exchange Commission (�SEC�) filings of OraSure Technologies,
including its registration statements, its Annual Report on Form
10-K for the year ended December 31, 2005, its Quarterly Reports on
Form 10-Q, and its other filings with the SEC. Although
forward-looking statements help to provide complete information
about future prospects, readers should keep in mind that
forward-looking statements may not be reliable. The forward-looking
statements are made as of the date of this press release and
OraSure Technologies undertakes no duty to update these statements.
OraSure Technologies, Inc. (NASDAQ: OSUR), a market leader in oral
fluid diagnostics, today announced revenues of $17.6 million for
the quarter ended September 30, 2006, compared to $18.1 million in
revenues recorded for the comparable period in 2005. The Company's
net income was $2.1 million, or $0.05 per share on a basic and
fully-diluted basis, for the third quarter of 2006, which includes
charges for stock option expense and a provision for income taxes,
neither of which were included in the Company's 2005 results.
Excluding these two charges, net income for the third quarter of
2006 would have been $4.3 million, or $0.09 per share on a
fully-diluted basis. These results compare to net income of $3.8
million, or $0.08 per share on a basic and fully-diluted basis,
during the third quarter of 2005. For the nine months ended
September 30, 2006, the Company had revenues of $50.4 million
compared to revenues of $51.3 million for the nine months ended
September 30, 2005. The Company recorded net income of $4.2
million, or $0.09 per share on a basic and fully-diluted basis, for
the nine months ended September 30, 2006, which includes charges
for stock option expense and a provision for income taxes.
Excluding these two charges, net income for the nine months ended
September 30, 2006 would have been $10.0 million, or $0.21 per
share on a fully-diluted basis. These results compare to net income
of $6.8 million, or $0.15 per share on a basic and fully-diluted
basis, during the nine months ended September 30, 2005, which
excluded costs related to stock options and a provision for income
taxes. "We are pleased with the Company's financial performance for
the third quarter," said Douglas A. Michels, President and Chief
Executive Officer of OraSure Technologies. "Our financial results
exceeded our expectations and were driven primarily by continued
strong performance of our infectious disease testing business along
with the increased sales of our substance abuse testing and
insurance risk assessment products. Offsetting these increases was
a reduction in our cryosurgical systems sales." Gross margin in
both the third quarters of 2006 and 2005 was 64%. Operating
expenses for the third quarter of 2006 increased to $8.8 million
from $8.4 million in the comparable period in 2005. This increase
was primarily attributable to stock option expense, increased
research and development expenses and costs related to the
implementation of a new enterprise resource planning system, offset
by lower legal and advertising costs. Operating expenses for the
nine months ended September 30, 2006 were $27.3 million, compared
to $25.2 million for the comparable period in 2005. Cash, cash
equivalents and short-term investments totaled $89.5 million and
working capital was $98.1 million at September 30, 2006, compared
to $77.6 million and $90.7 million, respectively, at December 31,
2005. Cash flow from operations was $5.9 million for the third
quarter of 2006, up from the $3.6 million reported for the third
quarter of 2005. Cash flow from operations for the nine months
ended September 30, 2006 was $14.1 million, compared to $8.5
million for the comparable period in 2005. Due to the better than
expected financial performance in the third quarter of 2006, the
Company is raising its 2006 full year, fully-diluted earnings per
share guidance to between $0.10 - $0.11 per share as a result of an
additional expected $0.01 - $0.02 per share of earnings in the
fourth quarter of 2006. The fourth quarter earnings projection is
based on attainment of projected revenues of between $17.0 million
and $17.5 million for the quarter, resulting in 2006 full-year
projected revenues of between approximately $67.5 million and $68.0
million. -0- *T Condensed Financial Data (In thousands, except
per-share data and percentages) Unaudited Three months ended Nine
months ended September 30, September 30, -------------------
----------------- 2006 2005 2006 2005 ---------- -------- --------
-------- Results of Operations Revenues $17,639 $18,077 $50,421
$51,335 Cost of products sold 6,365 6,432 18,516 20,773 ----------
-------- -------- -------- Gross profit 11,274 11,645 31,905 30,562
Operating expenses: Research and development 1,753 1,298 5,150
3,750 Acquired in-process technology -- -- 600 -- Sales and
marketing 3,632 3,965 11,977 12,289 General and administrative
3,445 3,168 9,545 9,132 ---------- -------- -------- -------- Total
operating expenses 8,830 8,431 27,272 25,171 ---------- --------
-------- -------- Operating income 2,444 3,214 4,633 5,391 Other
income, net 955 594 2,642 1,421 Income tax provision 1,264 -- 3,033
-- ---------- -------- -------- -------- Net income $ 2,135 $ 3,808
$ 4,242 $ 6,812 ========== ======== ======== ======== Earnings per
share Basic $ 0.05 $ 0.08 $ 0.09 $ 0.15 ========== ========
======== ======== Diluted $ 0.05 $ 0.08 $ 0.09 $ 0.15 ==========
======== ======== ======== Shares used in computing earnings per
share: Basic 45,922 45,372 45,888 44,936 ========== ========
======== ======== Diluted 47,247 46,676 47,712 45,850 ==========
======== ======== ======== *T -0- *T Reconciliation of Non-GAAP
Three months ended Nine months ended Financial Measures September
30, September 30, ------------------ ----------------- 2006 2005
2006 2005 ---------- ------- --------- ------- Net income - before
charges $ 4,344 $3,808 $ 9,992 $6,812 Stock option expense 945 --
2,717 -- Income tax provision 1,264 -- 3,033 -- ---------- -------
--------- ------- Net income - GAAP basis $ 2,135 $3,808 $ 4,242
$6,812 ========== ======= ========= ======= Diluted earnings per
share - before charges $ 0.09 $ 0.08 $ 0.21 $ 0.15 Stock option
expense 0.02 -- 0.06 -- Income tax provision 0.02 -- 0.06 --
---------- ------- --------- ------- Diluted earnings per share -
GAAP basis $ 0.05 $ 0.08 $ 0.09 $ 0.15 ========== ======= =========
======= *T -0- *T Three months ended September 30,
---------------------------------------- Percentage of Dollars
Total Revenues ----------------- -------------- Market Revenues %
2006 2005 Change 2006 2005 -------- -------- ------- -------- -----
Infectious disease testing $ 7,536 $ 7,037 7% 42% 39% Substance
abuse testing 4,213 3,595 17 24 20 Cryosurgical systems 4,025 6,143
(34) 23 34 Insurance risk assessment 1,734 1,275 36 10 7 --------
-------- -------- ----- Product revenues 17,508 18,050 (3) 99 100
Licensing and product development 131 27 385 1 -- -------- --------
-------- ----- Total revenues $17,639 $18,077 (2)% 100% 100%
======== ======== ======== ===== Nine months ended September 30,
---------------------------------------- Percentage of Dollars
Total Revenues ----------------- -------------- % Market Revenues
2006 2005 Change 2006 2005 -------- -------- ------- -------- -----
Infectious disease testing $21,239 $19,672 8% 42% 38% Substance
abuse testing 11,694 10,060 16 23 20 Cryosurgical systems 13,063
16,002 (18) 26 31 Insurance risk assessment 4,128 5,364 (23) 8 11
-------- -------- -------- ----- Product revenues 50,124 51,098 (2)
99 100 Licensing and product development 297 237 25 1 -- --------
-------- -------- ----- Total revenues $50,421 $51,335 (2)% 100%
100% ======== ======== ======== ===== *T -0- *T September 30,
December 31, Balance Sheets 2006 2005 ------------- ------------
Assets ------------------------------------------- Cash, cash
equivalents and short-term investments $ 89,534 $ 77,620 Accounts
receivable, net 10,236 11,602 Inventories 4,812 4,128 Current
portion of deferred income taxes 3,511 6,504 Other current assets
1,646 1,553 Property and equipment, net 16,478 5,815 Deferred
income taxes 20,580 20,205 Other non-current assets 2,938 3,320
------------- ------------ Total assets $ 149,735 $ 130,747
============= ============ Liabilities and Stockholders' Equity
------------------------------------------- Current portion of
long-term debt $ 636 $ 456 Accounts payable 2,519 2,547 Accrued
expenses 8,526 7,734 Long-term debt, less current portion 10,303
884 Other liabilities 375 207 Stockholders' equity 127,376 118,919
------------- ------------ Total liabilities and stockholders'
equity $ 149,735 $ 130,747 ============= ============ *T Non-GAAP
Financial Measures Net income - before charges and diluted earnings
per share - before charges, each exclude the impact of stock option
expensing and income tax provisions. These financial measures
should not be considered an alternative to net income or diluted
earnings per share, respectively, which are indicators of operating
performance determined in accordance with GAAP. OraSure
Technologies believes that net income - before charges and diluted
earnings per share - before charges, although non-GAAP financial
measures, are also useful and meaningful to investors because they
provide investors with the Company's underlying earnings
performance as another criterion in making their investment
decisions. OraSure's management also uses these calculations in
measuring certain corporate performance goals. Other companies may
use different measures to present financial information. Conference
Call The Company will host a conference call and audio webcast
today to discuss the Company's third quarter 2006 financial results
and to provide an update on major business objectives, beginning at
5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). On the call will
be Douglas A. Michels, President and Chief Executive Officer, and
Ronald H. Spair, Chief Financial Officer and Chief Operating
Officer. The call will include remarks by management and a question
and answer session. In order to listen to the conference call,
please either dial 888-742-2024 (Domestic) or 706-643-0033
(International), or go to OraSure Technologies' Web site,
www.orasure.com, and click on the Investor Info link. A replay of
the call will be archived on OraSure Technologies' web site shortly
after the call has ended and will be available for seven days. A
replay of the call can also be accessed until November 08, 2006, by
dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and
entering the Conference ID #8995949. About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral fluid
specimen collection devices and tests and other diagnostic products
using its proprietary technologies, including immunoassays and
other in vitro diagnostic tests and other medical devices. These
products are sold in the United States and certain foreign
countries to clinical laboratories, hospitals, clinics,
community-based organizations and other public health
organizations, distributors, government agencies, physicians'
offices, and commercial and industrial entities. For more
information on the Company, please visit www.orasure.com. Important
Information This press release contains certain forward-looking
statements, including with respect to revenues and earnings per
share. Actual results could be significantly different. Factors
that could affect results include the ability to market and sell
products; changes in relationships with strategic partners and
reliance on strategic partners for the performance of critical
activities under collaborative arrangements; failure of
distributors or other customers to meet purchase forecasts or
minimum purchase requirements for our products; impact of
competitors, competing products and technology changes; ability to
develop, commercialize and market new products; market acceptance
of oral fluid testing or other new products or technology; changes
in market acceptance based on product performance; continued bulk
purchases by customers, including governmental agencies, and the
ability to fully deploy those purchases in a timely manner; ability
to fund research and development and other products and operations;
ability to obtain and maintain new or existing product distribution
channels; reliance on sole supply sources for critical product
components; availability of related products produced by third
parties; ability to obtain, and timing and cost of obtaining,
necessary regulatory approval for new products or new indications
or applications for existing products; ability to comply with
applicable regulatory requirements; history of losses and ability
to achieve sustained profitability; volatility of our stock price;
uncertainty relating to patent protection and potential patent
infringement claims; uncertainty and costs of litigation relating
to patents and other intellectual property; availability of
licenses to patents or other technology; ability to enter into
international manufacturing agreements; obstacles to international
marketing and manufacturing of products; ability to sell products
internationally; loss or impairment of sources of capital; ability
to meet financial covenants in agreements with financial
institutions; ability to retain qualified personnel; exposure to
product liability, patent infringement, and other types of
litigation; changes in international, federal or state laws and
regulations; customer consolidations and inventory practices;
equipment failures and ability to obtain needed raw materials and
components; the impact of terrorist attacks and civil unrest;
ability to complete consolidation or restructuring activities;
ability to identify, complete and realize the full benefits of
potential acquisitions; and general political, business and
economic conditions. These and other factors are discussed more
fully in the Securities and Exchange Commission ("SEC") filings of
OraSure Technologies, including its registration statements, its
Annual Report on Form 10-K for the year ended December 31, 2005,
its Quarterly Reports on Form 10-Q, and its other filings with the
SEC. Although forward-looking statements help to provide complete
information about future prospects, readers should keep in mind
that forward-looking statements may not be reliable. The
forward-looking statements are made as of the date of this press
release and OraSure Technologies undertakes no duty to update these
statements.
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Lug 2023 a Lug 2024